• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 3, 2011

View Archived Issues

Two Studies Describe How Taxol Resistance Develops

Two groups of scientists – led by researchers from Genentech Inc. and Beth Israel Deaconess Medical Center, respectively – have reported on why some cancer cells are resistant to drugs, such as Taxol, that target microtubules. Such drugs are among the most widely prescribed chemotherapeutic agents. Read More

Biotech Foundations: Sabin Targets Vaccine R&D for 'Diseases of the Poor'

The Sabin Vaccine Institute is on a mission not only to bring vaccines for neglected tropical diseases (NTD) to residents of some of the world's poorest countries, but also to help nurture world peace. Peter J. Hotez, president of the institute and research professor at George Washington University (GWU) in Washington, characterizes the institute's mission as "vaccine diplomacy," noting that the U.S. has an unprecedented opportunity to improve relations with Islamic nations by helping to ease the burden of disease in those countries. Read More

Financings Roundup

BerGenBio A/S, of Bergen, Norway, secured NOK7 million (US$1.3 million) from local Sarsia Seed and Development Funds to continue its R&D activities in cancer. The firm is working on its CellSelect platform, which uses information from RNAi screening studies to identify drug targets Read More

Stock Movers

Read More

Other News To Note

OncoMed Pharmaceuticals Inc., of Redwood City, Calif., said preclinical data demonstrated its lead candidate, OMP-21M18, inhibits tumor growth and reduces cancer stem cell frequency when administered alone or in combination with chemotherapy in human colorectal cancer tumors with or without KRAS mutations. The data were published in the March 1, 2011, issue of Cancer Research. Read More

GTx Nixes Toremifene After Ipsen Terminates Partnership

GTx Inc. plans to walk away from toremifene after the company "mutually agreed to terminate" its collaboration with Ipsen Group SA to develop and commercialize the drug, GTx CEO Mitchell Steiner told BioWorld Today. Read More

Clinic Roundup

The European Medicines Agency gave Vical Inc., of San Diego, scientific advice pertaining to its endpoints for a Phase III trial of TransVax, a cytomegalovirus vaccine. The EMA said that a CMV disease endpoint was not practical, because of the low incidence of CMV disease and the small size of the target population. Vical is also working on plans for a pivotal Phase III trial with the FDA. Read More

Cladribine Falters, Biotech MS Candidates Move Up

A complete response letter caps the latest chapter in the troubled tale of EMD Serono Inc.'s cladribine tablets for relapsing and remitting multiple sclerosis (MS). The German company, an affiliate of Merck KGaA, has struggled to get the drug through the U.S. and European regulatory gauntlet, suffering setbacks nearly every step of the way. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Ligachem inks two mystery ADC deals with CSPC subsidiary Novarock

    BioWorld
    Ligachem Biosciences Inc. signed two license agreements with Novarock Biotherapeutics Inc., a subsidiary of CSPC Pharmaceutical Group Ltd., to bring in two of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe